These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 23426947)

  • 1. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
    Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
    Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of tolerance to human factor VIII in mice.
    Chao H; Walsh CE
    Blood; 2001 May; 97(10):3311-2. PubMed ID: 11342466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
    Evans GL; Morgan RA
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
    Nguyen GN; Lindgren JR; Seleme MC; Kafle S; Zander CB; Zheng XL; Sabatino DE
    J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.
    Chavez CL; Keravala A; Chu JN; Farruggio AP; Cuéllar VE; Voorberg J; Calos MP
    Hum Gene Ther; 2012 Apr; 23(4):390-8. PubMed ID: 22077817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
    Sarkar R; Xiao W; Kazazian HH
    J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.